Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500114830) titled 'A randomized, open, two-agent, single-dose postprandial bioequivalence trial of arbidol hydrochloride tablets in healthy subjects' on Dec. 17, 2025.
Study Type: Interventional study
Study Design:
Cross-over
Primary Sponsor: The Second Hospital of Hebei Medical University
Condition:
None
Intervention:
A (T)(R) :First-cycle oral test formulation (T), second-cycle oral reference formulation (R)
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2023-05-05
Target Sample Size: A (T)(R) :24; B(R)(T):24;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn...